Drug intelligence / Profile preview

CG-8020

Development stage: Unknown
Lead developer: ANI Pharmaceuticals
Modality: Cell Therapies

Overview

CG-8020 is an investigational cell therapy developed by Cell Genesys for the treatment of neoplasms, digestive system disorders, and endocrinology and metabolic diseases. It has been studied in combination with another agent, CG-2505, particularly for pancreatic cancer. The precise mechanism of action and molecular targets have not been disclosed publicly. The highest reported clinical development phase for this combination is Phase 2 in the United States[1][2][3].

Brand names: GVAX Pancreas
Other names: Allogeneic GM-CSF-secreting pancreatic cancer cell line

Beyond the preview

Go deeper on CG-8020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG-8020.

Explore the full profile